schliessen

Filtern

 

Bibliotheken

Doxorubicin in sterically stabilized liposomes

Doxorubicin is the first FDA-approved liposomal therapeutic drug in the US and is being used in the treatment of Kaposi sarcoma. The drug is encapsulated due to its precipitation with sulphate in the liposome interior. More than 2,000 patients with Kaposi sarcoma have been treated with doxorubicin,... Full description

Journal Title: Nature April 11, 1996, Vol.380(6574), p.561(2)
Main Author: Lasic, Danilo D.
Format: Electronic Article Electronic Article
Language:
Subjects:
ID: ISSN: 0028-0836
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: gale_ofa18434201
title: Doxorubicin in sterically stabilized liposomes
format: Article
creator:
  • Lasic, Danilo D.
subjects:
  • Doxorubicin -- Evaluation
  • Liposomes -- Physiological Aspects
  • Kaposi's Sarcoma
  • Chemotherapy
ispartof: Nature, April 11, 1996, Vol.380(6574), p.561(2)
description: Doxorubicin is the first FDA-approved liposomal therapeutic drug in the US and is being used in the treatment of Kaposi sarcoma. The drug is encapsulated due to its precipitation with sulphate in the liposome interior. More than 2,000 patients with Kaposi sarcoma have been treated with doxorubicin, which shows reduced toxicity and a high response rate. Enhanced liposome activity and drug retention substantially increases the anticancer activity of doxorubicin. The drug delivery system of liposomes is discussed.
language:
source:
identifier: ISSN: 0028-0836
fulltext: fulltext
issn:
  • 0028-0836
  • 00280836
url: Link


@attributes
ID1772629300
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid18434201
sourceidgale_ofa
recordidTN_gale_ofa18434201
sourceformatXML
sourcesystemOther
pqid78012150
galeid18434201
display
typearticle
titleDoxorubicin in sterically stabilized liposomes
creatorLasic, Danilo D.
ispartofNature, April 11, 1996, Vol.380(6574), p.561(2)
identifierISSN: 0028-0836
subjectDoxorubicin -- Evaluation ; Liposomes -- Physiological Aspects ; Kaposi's Sarcoma ; Chemotherapy
descriptionDoxorubicin is the first FDA-approved liposomal therapeutic drug in the US and is being used in the treatment of Kaposi sarcoma. The drug is encapsulated due to its precipitation with sulphate in the liposome interior. More than 2,000 patients with Kaposi sarcoma have been treated with doxorubicin, which shows reduced toxicity and a high response rate. Enhanced liposome activity and drug retention substantially increases the anticancer activity of doxorubicin. The drug delivery system of liposomes is discussed.
source
version8
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
scope
0gale_onefilea
1gale_onefileg
2OneFile
creatorcontribLasic, Danilo D
titleDoxorubicin in sterically stabilized liposomes.
descriptionDoxorubicin is the first FDA-approved liposomal therapeutic drug in the US and is being used in the treatment of Kaposi sarcoma. The drug is encapsulated due to its precipitation with sulphate in the liposome interior. More than 2,000 patients with Kaposi sarcoma have been treated with doxorubicin, which shows reduced toxicity and a high response rate. Enhanced liposome activity and drug retention substantially increases the anticancer activity of doxorubicin. The drug delivery system of liposomes is discussed.
subject
0Doxorubicin--Evaluation
1Liposomes--Physiological aspects
2Kaposi's sarcoma
general
0Nature Publishing Group
1Cengage Learning, Inc.
sourceidgale_ofa
recordidgale_ofa18434201
issn
00028-0836
100280836
rsrctypearticle
creationdate1996
recordtypearticle
addtitleNature
searchscopeOneFile
lsr30VSR-Enriched:[pqid, doi, pages, galeid, eissn]
sort
titleDoxorubicin in sterically stabilized liposomes.
authorLasic, Danilo D.
creationdate19960411
facets
frbrgroupid-2122889009156470508
frbrtype5
creationdate1996
topic
0Doxorubicin–Evaluation
1Liposomes–Physiological Aspects
2Kaposi's Sarcoma
3Chemotherapy
collectionOneFile (GALE)
prefilterarticles
rsrctypearticles
creatorcontribLasic, Danilo D.
jtitleNature
toplevelpeer_reviewed
frbr
t2
k11996
k200280836
k4380
k56574
k6561
k7nature
k8doxorubicin in sterically stabilized liposomes
k9doxorubicininstericasomes
k12doxorubicininstericallyst
k15danilodlasic
k16lasicdanilod
delivery
delcategoryRemote Search Resource
fulltextfulltext
ranking
booster11
booster21
pcg_typeaggregator
addata
auLasic, Danilo D.
atitleDoxorubicin in sterically stabilized liposomes.
jtitleNature
risdate19960411
volume380
issue6574
spage561
issn0028-0836
genrearticle
ristypeJOUR
abstractDoxorubicin is the first FDA-approved liposomal therapeutic drug in the US and is being used in the treatment of Kaposi sarcoma. The drug is encapsulated due to its precipitation with sulphate in the liposome interior. More than 2,000 patients with Kaposi sarcoma have been treated with doxorubicin, which shows reduced toxicity and a high response rate. Enhanced liposome activity and drug retention substantially increases the anticancer activity of doxorubicin. The drug delivery system of liposomes is discussed.
pubNature Publishing Group
lad01gale_ofa
doi10.1038/380561a0
pages561-561
eissn14764687
date1996-04-11